Difference between revisions of "Vindesine (Eldisine)"
Jump to navigation
Jump to search
m (Text replacement - "[[Media:" to "[[File:") |
m (Text replacement - "[[File:" to "[[:File:") |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/D6279B9B-2F71-4784-8AF8-D1452648635C/19507/Vindesinemonograph_3Nov07.pdf Vindesine (Eldisine) package insert]</ref><ref>[[File:Vindesine.pdf | Vindesine (Eldisine) package insert (locally hosted backup)]]</ref> | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/D6279B9B-2F71-4784-8AF8-D1452648635C/19507/Vindesinemonograph_3Nov07.pdf Vindesine (Eldisine) package insert]</ref><ref>[[:File:Vindesine.pdf | Vindesine (Eldisine) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
Revision as of 03:56, 20 September 2021
Not approved by the FDA. Approved for use in some countries e.g., U.K., South Africa.
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Burkitt lymphoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- HIV-associated lymphoma
- Melanoma
- Non-small cell lung cancer
- Post-transplant lymphoproliferative disorder
- Small cell lung cancer
Patient drug information
- Vindesine (Eldisine) patient information at Macmillan Cancer Support[3]
- Vindesine (Eldisine) patient information at Genus Pharmaceuticals[4]
- Vindesine (Eldisine) patient drug information (UpToDate)[5]
Also known as
- Code name: LY-099094
- Generic names: desacetylvinblastine amide, DAVA, DVA, VDS
- Brand names: Eldesine, Eldisin, Eldisine, Enison, Fildesin, Gesidine
References
- ↑ 1.0 1.1 Vindesine (Eldisine) package insert
- ↑ Vindesine (Eldisine) package insert (locally hosted backup)
- ↑ Vindesine (Eldisine) patient information at Macmillan Cancer Support
- ↑ Vindesine (Eldisine) patient information at Genus Pharmaceuticals
- ↑ Vindesine (Eldisine) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Adult T-cell leukemia-lymphoma medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Melanoma medications
- Non-small cell lung cancer medications
- Post-transplant lymphoproliferative disorder medications
- Small cell lung cancer medications